Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients

A. Passaro, A. Prelaj, A. Pochesci, G. Spitaleri, G. Rossi, E. Del Signore, C. Catania, F. De Marinis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease. Nowadays, brigatinib is under evaluation in different clinical trials exploring TKI-naive patients in the first-line setting. On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

Original languageEnglish
Pages (from-to)435-446
Number of pages12
JournalDrugs of Today
Volume53
Issue number8
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Clinical Trials
Therapeutics
anaplastic lymphoma kinase
Mutation
crizotinib

Keywords

  • ALK
  • Brain metastases
  • Brigatinib
  • Crizotinib
  • Lung cancer
  • NSCLC
  • Resistance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients. / Passaro, A.; Prelaj, A.; Pochesci, A.; Spitaleri, G.; Rossi, G.; Del Signore, E.; Catania, C.; De Marinis, F.

In: Drugs of Today, Vol. 53, No. 8, 01.08.2017, p. 435-446.

Research output: Contribution to journalArticle

@article{690e296603544957affd906caf7575f3,
title = "Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients",
abstract = "Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease. Nowadays, brigatinib is under evaluation in different clinical trials exploring TKI-naive patients in the first-line setting. On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.",
keywords = "ALK, Brain metastases, Brigatinib, Crizotinib, Lung cancer, NSCLC, Resistance",
author = "A. Passaro and A. Prelaj and A. Pochesci and G. Spitaleri and G. Rossi and {Del Signore}, E. and C. Catania and {De Marinis}, F.",
year = "2017",
month = "8",
day = "1",
doi = "10.1358/dot.2017.53.8.2676119",
language = "English",
volume = "53",
pages = "435--446",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "8",

}

TY - JOUR

T1 - Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients

AU - Passaro, A.

AU - Prelaj, A.

AU - Pochesci, A.

AU - Spitaleri, G.

AU - Rossi, G.

AU - Del Signore, E.

AU - Catania, C.

AU - De Marinis, F.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease. Nowadays, brigatinib is under evaluation in different clinical trials exploring TKI-naive patients in the first-line setting. On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

AB - Brigatinib (AP-26113, Alunbrig) is a second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) that is highly active in non-small cell lung cancer (NSCLC) harboring ALK translocation. Brigatinib was found to be very active against different ALK resistance mutations that mediate acquired resistance biology processes, particularly G1269A ALK C1156Y, I1171S/T, V1180L and others. Different clinical trials evaluated the activity of brigatinib in crizotinib-resistant patients, confirming high activity with durable response not only in parenchymal disease, but also in intracranial disease. Nowadays, brigatinib is under evaluation in different clinical trials exploring TKI-naive patients in the first-line setting. On the basis of its significant activity results, brigatinib received approval by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.

KW - ALK

KW - Brain metastases

KW - Brigatinib

KW - Crizotinib

KW - Lung cancer

KW - NSCLC

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=85032954662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032954662&partnerID=8YFLogxK

U2 - 10.1358/dot.2017.53.8.2676119

DO - 10.1358/dot.2017.53.8.2676119

M3 - Article

VL - 53

SP - 435

EP - 446

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 8

ER -